_|PRE-PANDEMIC VACCINES: OTHER APPROACHES (M2e)|_

[Giuseppe]

VaxInnate to discuss seasonal and pandemic flu vaccines during BIO 2008 this week

Company's novel vaccine technology could revolutionize production of flu vaccines with enhanced potency, manufacturing capacity and cost-effectiveness

SAN DIEGO, CA, June 16, 2008 --

VaxInnate Corporation announced today that it will discuss its novel proprietary technology for producing seasonal and pandemic influenza vaccines during BIO 2008 here this week.

VaxInnate will participate in the following three BIO 2008 panel discussions:

** On Tuesday, June 17th

-- "Influenza Research and Surveillance: Preparing for the Next Pandemic,"
- 8:15-9:45 am in Room 29A ? including Robert Becker, PhD, MBA, VaxInnate's Vice President of Business Development

** On Thursday, June 19th

-- "Vaccine Renaissance,"
- 8:30-10:00 am, Room 29A ? including Dr. Robert Becker

- "Moore's Law for Biomanufacturing: Innovation in a Maturing Biologicals Industry,"

** 4:00 - 5:30 pm, Room 29B ? including Edward Arcuri, PhD, VaxInnate's Chief of Operations (COO)

VaxInnate's Approach
VaxInnate's novel technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of influenza vaccines.

VaxInnate's approach to developing and producing influenza vaccines is based upon a proprietary combination of toll-like receptor (TLR) mediated immune enhancement and recombinant bacterial production of vaccine antigen.

This proprietary technology could significantly reduce the time required to produce supplies of influenza vaccine sufficient to meet national and even global needs.

VaxInnate's use of bacterial expression for production of influenza vaccines does not require costly expansion of manufacturing capacity, as do other influenza vaccine products.

Due to its efficiency and transferability, VaxInnate's flu vaccine could instead be produced in existing biotechnology facilities that have microbial production capacity.

No other vaccine technology in use or in development today has these same potential capabilities.

Results of a Phase I study of VaxInnate's M2e universal vaccine candidate will be available this summer.

The company plans to present the study data at a major scientific conference later this year and publish the data in a peer-reviewed journal.

###
The Phase I study was supported by a $9.5 million grant awarded to the University of Texas Medical Branch (UTMB) by the Bill & Melinda Gates Foundation for better control of influenza epidemics in the developing world.

About VaxInnate
VaxInnate is a privately-held biotechnology company located in Cranbury, NJ and New Haven, CT that is pioneering breakthrough technology for use in developing novel, proprietary vaccines for seasonal and pandemic influenza. This novel technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of influenza vaccines.

In addition to the M2e universal vaccine candidate in clinical development, clinical trials for hemagglutinin (HA)-based seasonal and pandemic influenza vaccine candidates will begin this year.

VaxInnate's technology platform is also being investigated for development of vaccines for other diseases. For more information about VaxInnate, please visit http://www.vaxinnate.com.


-
http://www.eurekalert.org/pub_releases/2008-06/v-vtd061208.php
-------

 

[Shiloh]

Re: _|PRE-PANDEMIC VACCINES: OTHER APPROACHES (M2e)|_

Source: http://www.sciencedaily.com/releases/2008/08/080821164258.htm

Researchers Test New Vaccine To Fight Multiple Influenza Strains

ScienceDaily (Aug. 22, 2008) ? A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.

Turley, who is director of clinical trials and clinical research at the Sealy Center for Vaccine Development at UTMB and the study's principal investigator, said that VaxInnate's M2e universal vaccine could possibly protect against seasonal and pandemic influenza strains.

"We'd characterize this influenza vaccine candidate as very promising, based upon the immune responses and tolerability we saw in the clinical trial participants," Turley said. "UTMB is committed to further studies of the vaccine candidate, which has the potential to be a safe, highly effective and much-needed option to prevent seasonal and pandemic influenza A."

The results of the study will be presented at the Oct.25-28 joint meeting of the Interscience Conference on Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA).

The study was supported by a $9.5 million grant awarded to UTMB by the Bill & Melinda Gates Foundation.

The trial involved 60 young adults in a double-blind, dose-escalating, first time in human, Phase I study to assess the safety and immunogenicity, or the ability to produce a response in the immune system, of the vaccine.

The trial was also designed to evaluate the methods used by VaxInnate to develop and produce flu vaccines. The company uses a proprietary combination of toll-like receptor-mediated immune enhancement and recombinant bacterial production of vaccine antigen. This proprietary technology could significantly reduce the time required to produce vaccine supplies sufficient to meet national demand, and provide a solution to international influenza vaccine needs which are unmet in all but the developed world.

Adapted from materials provided by University of Texas Medical Branch at Galveston.